Zevra Therapeutics, Inc. (ZVRA) stock
ZVRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3060% below fair value
$9.07−0.21 (-2.26%)
Close on Nov 19, 2026Market cap $538.61MP/E 9.8Yield –
Zevra Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Zevra Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $136.07M, up 119.4% year over year. For fiscal 2025 it was $106.47M, up 350.9% from the year before. The highest annual figure on record is $106.47M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $106.47M | +350.9% |
| FY2024 | Dec 31, 2024 | $23.61M | -14.0% |
| FY2023 | Dec 31, 2023 | $27.46M | +170.3% |
| FY2022 | Dec 31, 2022 | $10.16M | -64.5% |
| FY2021 | Dec 31, 2021 | $28.65M | +115.6% |
| FY2020 | Dec 31, 2020 | $13.29M | +3.5% |
| FY2019 | Dec 31, 2019 | $12.84M | – |
| FY2018 | Dec 31, 2018 | $0 | – |
| FY2015 | Dec 31, 2015 | $0 | – |
| FY2014 | Dec 31, 2014 | $0 | – |
| FY2013 | Dec 31, 2013 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $39.66M | +53.3% |
| Q1 FY2026 | Mar 31, 2026 | $36.22M | +77.5% |
| Q4 FY2025 | Dec 31, 2025 | $34.13M | +183.4% |
| Q3 FY2025 | Sep 30, 2025 | $26.06M | +605.4% |
| Q2 FY2025 | Jun 30, 2025 | $25.88M | +481.7% |
| Q1 FY2025 | Mar 31, 2025 | $20.40M | +495.6% |
| Q4 FY2024 | Dec 31, 2024 | $12.04M | -6.8% |
| Q3 FY2024 | Sep 30, 2024 | $3.70M | +27.6% |
| Q2 FY2024 | Jun 30, 2024 | $4.45M | -47.5% |
| Q1 FY2024 | Mar 31, 2024 | $3.43M | +7.8% |
| Q4 FY2023 | Dec 31, 2023 | $12.92M | +539.0% |
| Q3 FY2023 | Sep 30, 2023 | $2.90M | +0.7% |
| Q2 FY2023 | Jun 30, 2023 | $8.47M | +551.5% |
| Q1 FY2023 | Mar 31, 2023 | $3.18M | -19.9% |
| Q4 FY2022 | Dec 31, 2022 | $2.02M | -21.7% |
| Q3 FY2022 | Sep 30, 2022 | $2.87M | +46.3% |
| Q2 FY2022 | Jun 30, 2022 | $1.30M | -89.2% |
| Q1 FY2022 | Mar 31, 2022 | $3.97M | -67.3% |
| Q4 FY2021 | Dec 31, 2021 | $2.58M | +9.1% |
| Q3 FY2021 | Sep 30, 2021 | $1.97M | +2.1% |
| Q2 FY2021 | Jun 30, 2021 | $11.99M | +73.5% |
| Q1 FY2021 | Mar 31, 2021 | $12.12M | +480.0% |
| Q4 FY2020 | Dec 31, 2020 | $2.37M | +71.9% |
| Q3 FY2020 | Sep 30, 2020 | $1.93M | -83.2% |
| Q2 FY2020 | Jun 30, 2020 | $6.91M | – |
| Q1 FY2020 | Mar 31, 2020 | $2.09M | – |
| Q4 FY2019 | Dec 31, 2019 | $1.38M | – |
| Q3 FY2019 | Sep 30, 2019 | $11.46M | – |
| Q1 FY2019 | Mar 31, 2019 | $0 | – |
| Q4 FY2018 | Dec 31, 2018 | $0 | – |
| Q3 FY2018 | Sep 30, 2018 | $0 | – |
See a number that looks wrong?